vs
Medpace Holdings, Inc.（MEDP）与Reddit, Inc.（RDDT）财务数据对比。点击上方公司名可切换其他公司
Reddit, Inc.的季度营收约是Medpace Holdings, Inc.的1.0倍（$725.6M vs $708.5M），Reddit, Inc.净利率更高（34.7% vs 19.1%，领先15.6%），Reddit, Inc.同比增速更快（69.7% vs 32.0%），Reddit, Inc.自由现金流更多（$263.6M vs $188.1M），过去两年Reddit, Inc.的营收复合增速更高（72.8% vs 17.7%）
Medpace Holdings, Inc.是总部位于美国俄亥俄州辛辛那提的全球性临床研究机构（CRO），现有员工约6000人。公司采用全服务运营模式，可提供全球中心实验室、影像核心实验室、生物分析实验室服务，且在总部临床研究园区内设有I期临床试验单元。
Reddit是美国知名的社交新闻聚合与论坛类社交媒体平台，注册用户可发布链接、文字帖、图片、视频等各类内容，其他用户可对内容进行点赞或点踩，内容按主题归类到用户创建的子板块中，获赞更高的内容会排在板块前列，热度足够的内容还将展示在全站首页。
MEDP vs RDDT — 直观对比
营收规模更大
RDDT
是对方的1.0倍
$708.5M
营收增速更快
RDDT
高出37.6%
32.0%
净利率更高
RDDT
高出15.6%
19.1%
自由现金流更多
RDDT
多$75.5M
$188.1M
两年增速更快
RDDT
近两年复合增速
17.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $708.5M | $725.6M |
| 净利润 | $135.1M | $251.6M |
| 毛利率 | — | 91.9% |
| 营业利润率 | 21.6% | 31.9% |
| 净利率 | 19.1% | 34.7% |
| 营收同比 | 32.0% | 69.7% |
| 净利润同比 | 15.5% | 254.2% |
| 每股收益（稀释后） | $4.65 | $1.24 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MEDPRDDT
| Q4 25 | $708.5M | $725.6M | ||
| Q3 25 | $659.9M | $584.9M | ||
| Q2 25 | $603.3M | $499.6M | ||
| Q1 25 | $558.6M | $392.4M | ||
| Q4 24 | $536.6M | $427.7M | ||
| Q3 24 | $533.3M | $348.4M | ||
| Q2 24 | $528.1M | $281.2M | ||
| Q1 24 | $511.0M | $243.0M |
净利润MEDPRDDT
| Q4 25 | $135.1M | $251.6M | ||
| Q3 25 | $111.1M | $162.7M | ||
| Q2 25 | $90.3M | $89.3M | ||
| Q1 25 | $114.6M | $26.2M | ||
| Q4 24 | $117.0M | $71.0M | ||
| Q3 24 | $96.4M | $29.9M | ||
| Q2 24 | $88.4M | $-10.1M | ||
| Q1 24 | $102.6M | $-575.1M |
毛利率MEDPRDDT
| Q4 25 | — | 91.9% | ||
| Q3 25 | — | 91.0% | ||
| Q2 25 | — | 90.8% | ||
| Q1 25 | — | 90.5% | ||
| Q4 24 | — | 92.6% | ||
| Q3 24 | — | 90.1% | ||
| Q2 24 | — | 89.5% | ||
| Q1 24 | — | 88.6% |
营业利润率MEDPRDDT
| Q4 25 | 21.6% | 31.9% | ||
| Q3 25 | 21.5% | 23.7% | ||
| Q2 25 | 20.9% | 13.6% | ||
| Q1 25 | 20.3% | 1.0% | ||
| Q4 24 | 23.4% | 12.4% | ||
| Q3 24 | 21.1% | 2.0% | ||
| Q2 24 | 19.9% | -11.0% | ||
| Q1 24 | 20.4% | -242.5% |
净利率MEDPRDDT
| Q4 25 | 19.1% | 34.7% | ||
| Q3 25 | 16.8% | 27.8% | ||
| Q2 25 | 15.0% | 17.9% | ||
| Q1 25 | 20.5% | 6.7% | ||
| Q4 24 | 21.8% | 16.6% | ||
| Q3 24 | 18.1% | 8.6% | ||
| Q2 24 | 16.7% | -3.6% | ||
| Q1 24 | 20.1% | -236.7% |
每股收益（稀释后）MEDPRDDT
| Q4 25 | $4.65 | $1.24 | ||
| Q3 25 | $3.86 | $0.80 | ||
| Q2 25 | $3.10 | $0.45 | ||
| Q1 25 | $3.67 | $0.13 | ||
| Q4 24 | $3.67 | $4.76 | ||
| Q3 24 | $3.01 | $0.16 | ||
| Q2 24 | $2.75 | $-0.06 | ||
| Q1 24 | $3.20 | $-8.19 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $497.0M | $953.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $459.1M | $2.9B |
| 总资产 | $2.0B | $3.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资MEDPRDDT
| Q4 25 | $497.0M | $953.6M | ||
| Q3 25 | $285.4M | $911.7M | ||
| Q2 25 | $46.3M | $734.1M | ||
| Q1 25 | $441.4M | $635.7M | ||
| Q4 24 | $669.4M | $562.1M | ||
| Q3 24 | $656.9M | $515.9M | ||
| Q2 24 | $510.9M | $468.0M | ||
| Q1 24 | $407.0M | $968.5M |
股东权益MEDPRDDT
| Q4 25 | $459.1M | $2.9B | ||
| Q3 25 | $293.6M | $2.6B | ||
| Q2 25 | $172.4M | $2.4B | ||
| Q1 25 | $593.6M | $2.2B | ||
| Q4 24 | $825.5M | $2.1B | ||
| Q3 24 | $881.4M | $2.0B | ||
| Q2 24 | $763.6M | $1.9B | ||
| Q1 24 | $671.5M | $1.8B |
总资产MEDPRDDT
| Q4 25 | $2.0B | $3.2B | ||
| Q3 25 | $1.8B | $2.9B | ||
| Q2 25 | $1.6B | $2.6B | ||
| Q1 25 | $1.9B | $2.4B | ||
| Q4 24 | $2.1B | $2.3B | ||
| Q3 24 | $2.1B | $2.2B | ||
| Q2 24 | $1.9B | $2.1B | ||
| Q1 24 | $1.8B | $2.0B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $192.7M | $266.8M |
| 自由现金流经营现金流 - 资本支出 | $188.1M | $263.6M |
| 自由现金流率自由现金流/营收 | 26.6% | 36.3% |
| 资本支出强度资本支出/营收 | 0.6% | 0.4% |
| 现金转化率经营现金流/净利润 | 1.43× | 1.06× |
| 过去12个月自由现金流最近4个季度 | $681.9M | $684.2M |
8季度趋势，按日历期对齐
经营现金流MEDPRDDT
| Q4 25 | $192.7M | $266.8M | ||
| Q3 25 | $246.2M | $185.2M | ||
| Q2 25 | $148.5M | $111.3M | ||
| Q1 25 | $125.8M | $127.6M | ||
| Q4 24 | $190.7M | $90.0M | ||
| Q3 24 | $149.1M | $71.6M | ||
| Q2 24 | $116.4M | $28.4M | ||
| Q1 24 | $152.7M | $32.1M |
自由现金流MEDPRDDT
| Q4 25 | $188.1M | $263.6M | ||
| Q3 25 | $235.5M | $183.1M | ||
| Q2 25 | $142.4M | $110.8M | ||
| Q1 25 | $115.8M | $126.6M | ||
| Q4 24 | $183.0M | $89.2M | ||
| Q3 24 | $138.5M | $70.3M | ||
| Q2 24 | $103.5M | $27.2M | ||
| Q1 24 | $147.2M | $29.2M |
自由现金流率MEDPRDDT
| Q4 25 | 26.6% | 36.3% | ||
| Q3 25 | 35.7% | 31.3% | ||
| Q2 25 | 23.6% | 22.2% | ||
| Q1 25 | 20.7% | 32.3% | ||
| Q4 24 | 34.1% | 20.8% | ||
| Q3 24 | 26.0% | 20.2% | ||
| Q2 24 | 19.6% | 9.7% | ||
| Q1 24 | 28.8% | 12.0% |
资本支出强度MEDPRDDT
| Q4 25 | 0.6% | 0.4% | ||
| Q3 25 | 1.6% | 0.4% | ||
| Q2 25 | 1.0% | 0.1% | ||
| Q1 25 | 1.8% | 0.2% | ||
| Q4 24 | 1.4% | 0.2% | ||
| Q3 24 | 2.0% | 0.4% | ||
| Q2 24 | 2.4% | 0.4% | ||
| Q1 24 | 1.1% | 1.2% |
现金转化率MEDPRDDT
| Q4 25 | 1.43× | 1.06× | ||
| Q3 25 | 2.22× | 1.14× | ||
| Q2 25 | 1.65× | 1.25× | ||
| Q1 25 | 1.10× | 4.88× | ||
| Q4 24 | 1.63× | 1.27× | ||
| Q3 24 | 1.55× | 2.40× | ||
| Q2 24 | 1.32× | — | ||
| Q1 24 | 1.49× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
RDDT
| Advertising | $689.7M | 95% |
| Other Revenue | $35.9M | 5% |
